

REMARKS/ARGUMENTS

The specification has been amended to (1) conform with the replacement drawing sheets submitted herewith; (2) correct an obvious error; and, (3) identify two cell lines producing the 10D5 and 3D6 antibodies, respectively, deposited with the ATTC. Thus, the amendments to the specification contain no new matter.

The paragraphs beginning on page 7, line 12 and p. 59, line 25 describe Figure 10; and to conform with the amendment to Figure 10; both paragraphs have been amended to identify the upper and lower panels of Figure 10 as Figure 10A and 10B, respectively. The paragraphs beginning on p. 16, line 16 and p. 62, line 12 have been amended to replace the plain text font of genus and species names with an italicized font; *e.g.*, "Salmonella" has been replaced with "*Salmonella*." The paragraph beginning on page 46, line 19 has been amended to correct an obvious error, *i.e.*, "that binds to A to the patient" has been amended to recite, "that binds to A β in the patient" and "of A β do not" has been amended to recite "of A β do not show."

The specification has been amended to conform with the five replacement sheets submitted herewith. The paragraph beginning on page 7, line 27 of the specification describes Figure 15. The paragraph has been replaced with six replacement paragraphs, which describe Figures 15A-15E, 15A, 15B, 15C, 15D, and 15E, respectively. The paragraph beginning on page 80, line 1 has also been amended to identify Figures 15A-15E. Additionally, the paragraphs beginning on page 76, line 17, and page 77, line 3, have been amended to conform the alum concentration to the alum concentration recited in Figure 15 as filed in Application No. 09/201,430, filed November 30, 1998, which is incorporated herein by reference.

Applicant deposited the cell line producing the antibody 10D5 and the cell line producing the antibody 3D6 with the ATCC on April 8, 2003. Applicant submits a statement under MPEP § 2406.02 under separate cover. The cell lines deposited with the ATCC are the cell lines producing the antibodies 10D5 and 3D6, respectively, which are identified in the instant specification, Application No. 09/580,518, filed May 26, 2000; U.S. Application No. 322,289 filed May 28, 1999; U.S. Application No. 09/201,430, filed November 30, 1998; and, U.S. Application No. 60/080,970, filed April 7, 1998. Applicants have amended the paragraphs beginning on p. 68, line 17, p. 83, line 14, and p. 107, line 26 of the specification to recite the

Application No. 09/724,940
First Preliminary Amendment Filed November 25, 2003

depository, accession number, and deposit date of the cell lines producing the 10D5 and 3D6 antibodies, respectively. These amendments do not add new matter (*see In re Lundak*, 227 USPQ 90 (Fed. Cir. 1985) and MPEP § 2406.01).

Applicant requests entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. A paper copy of the Sequence Listing is submitted herewith.

A Request to Reference Previously Filed Identical Computer Readable Copy According to 37 CFR 1.821(e) is submitted herewith.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:lah
60087509 v1